Objective To describe the patterns of prescription drug use among child and adolescent survivors of cancer in the early post-therapy period compared with matched peers without a cancer history.
Methods
We identified children and adolescents (age ≤21 years at end of treatment [EOT] ) treated for leukemia, lymphoma, CNS tumors, bone cancers, or gonadal cancers who completed therapy from January 1, 2000, to December 31, 2011, in the MarketScan Commercial Claims and Encounters Database. 15 This data source includes deidentified inpatient, outpatient, and pharmacy insurance claims data for >50 million individuals and their dependents who are insured by commercial health plans in the US. We identified children and adolescents with the aforementioned cancers using the Agency for Healthcare Research and Quality Clinical Classifications Software 16 matched to International Classification of Diseases, Ninth Revision, codes for the diagnoses of interest ( Table I ; available at www.jpeds.com). These 5 cancer types were selected for inclusion as they represent 5 of the most common childhood and adolescent cancers and provide a study sample from across this population's developmental spectrum. Survivors were required to have at least 2 cancer-related visits. We further required that patients have claims for chemotherapy, surgery, or radiation therapy (Table I) . EOT was defined as 30 days after the last observed treatment date. This included the date of the last inpatient or outpatient claim for chemotherapy or radiation therapy or the date at which an oral chemotherapy prescription would have concluded. We excluded patients with encounter diagnosis codes for 2 or more cancer types or who received a hematopoietic stem cell transplant. Patients were required to have 3 years of continuous health plan enrollment from EOT with no evidence of additional cancer treatment to provide a sufficient period of observation. Because data were available through 2015, subjects must have completed therapy before January 1, 2012, to allow for 3 years of observation.
We selected comparators from children and adolescents in the database without claims for a cancer diagnosis at any time in which they were enrolled in the health plan. Comparators were individually matched for 3-year continuous enrollment profile as determined by the matched survivor's EOT year, age, sex, and geographic region. Separate comparator cohorts were created for each cancer type. Comparators were randomly sampled at approximately a 10:1 ratio. The study design was reviewed by the University of North Carolina School of Medicine institutional review board and classified as not human subjects research.
Measures
The primary study outcomes were (1) any prescription fill, by cancer type and year post-therapy, and (2) drug class-specific use. Drug classes were defined via the Red Book classifications. 17 The proportions of survivors and comparators with at least 1 fill per year post-therapy were determined. The number of fills of unique drug classes per person, and the specific classes of these fills also were determined. Prescription fills among survivors were then categorized by therapeutic groups. Classspecific fills from the most commonly prescribed therapeutic groups among survivors (anti-infectives, CNS, hormonal, gastrointestinal, pulmonary, and cardiovascular agents) were compared with those among individuals without cancer.
Statistical Analyses
We compared the median number of prescriptions and unique drug classes filled by year between survivors and matched comparators using Wilcoxon rank-sum tests. The risk of classspecific prescription drug use by year for survivors and matched controls was estimated with unadjusted risk ratios (RRs) and 95% CIs. As a sensitivity analysis, RRs and 95% CIs were determined with a Poisson regression model adjusted for age, sex, region, and year to account for residual confounding after matching. Minimal differences were noted between the unadjusted and adjusted RRs, so the unadjusted estimates are presented. Statistical analyses were performed with SAS Version 9.4 (SAS Analytics, Cary, North Carolina).
Results

Study Sample
We identified 1414 survivors of childhood cancers and 14 007 matched comparators (Figure 1; ). There was a slight male predominance in the study sample (58%), with the highest sex differential among survivors of gonadal tumors (75% male). More patients were from the South and more were treated from 2009 to 2011, reflective of enrollment patterns for health plans included in the MarketScan database (Table II) .
Quantifying Prescription Fills among Survivors and Comparators
More survivors than comparators filled prescriptions. Across cancer types, 84%-91% of survivors filled at least 1 prescription in the first year off therapy, and this declined to 70%-81% by the third year post-therapy. Approximately 60% of comparators filled at least 1 prescription per year. Throughout the study period, survivors were at 20%-50% greater risk than comparators for having filled a prescription. This increase in prescription fills was present for survivors of all cancer types and across all 3 years of observation (Figure 2) .
In addition, survivors were more likely than comparators to fill prescriptions from multiple drug classes. Although survivors filled prescriptions from 4-8 drug classes per person in year 1, and 2-6 classes in years 2 and 3, comparators typically filled drugs in 1 class per year ( Table III) . Survivors of CNS tumors filled prescriptions from the most drug classes (6-8 classes/person-year), and survivors of gonadal tumors filled prescriptions from the fewest number of classes (2-4 classes/person-year).
Nearly one third of all prescriptions filled by survivors were for anti-infectives (antibacterials, antifungals, antivirals). Compared with individuals without a history of cancer, survivors of all cancer types were at increased risk for filling antibacterial prescriptions in all 3 years of the study period (Figure 3, Table IV [available at www.jpeds.com]). Although approximately 40% of comparators filled an antibacterial prescription each year, 50%-60% of survivors did so. Survivors of leukemia, lymphoma, and CNS tumors also were more likely to persistently fill antiviral and antifungal prescriptions (Table IV) .
A and
Nearly one-fourth of prescriptions filled by survivors were for CNS agents (opioids, antidepressants, anxiolytics, anticonvulsants). Fills for opioid pain medications were common among both survivors and comparators (12%-46% of survivors and 7%-13% of comparators) ( Table IV) . Versus comparators, risks for filling opioid prescriptions were 2.5 times greater for survivors of lymphoma (29% vs 13%, RR 2.3 [95% CI 1.96-2.80]) to >4 times greater for survivors of leukemia (31% vs 7%, RR 4.3 [3.66-5.14] ) during the first year off therapy. The risks declined with time but remained significantly greater among survivors even into the third year posttherapy (Figure 3, B) . Survivors also were at increased risk for receiving prescriptions of many psychoactive medications. (Figure 3, C) . A 2-to 7-fold increase in risk for anxiolytic use was observed among survivors of leukemia, lymphoma, CNS tumors, and bone cancers. Approximately 10% of patients with CNS and bone tumors filled a prescription for an anxiolytic in year 3. Stimulant prescriptions were overall not increased among survivors. Only among CNS tumor survivors and in the third year post-therapy did an increased risk for receiving a stimulant reach statistical significance (9% vs 5%, RR 1. (Table IV) . In addition, fills of thyroid hormone prescriptions were greater among survivors of CNS tumors, bone cancers, lymphoma, and leukemia (Figure 3 , D and Table IV) throughout the 3-year study period.
The risks for use of certain pulmonary and cardiovascular medications also were greater among survivors (Figure 3 , E and F). Notably, greater risks for inhaled bronchodilators were observed among survivors of leukemia and lymphoma beginning in the first post-therapy year and among survivors of gonadal tumors by the third year off therapy (leukemia 15% vs 10%, RR 1. 
Discussion
We provide an objective assessment of prescription drug use for >1400 childhood and adolescent cancer survivors and >14 000 matched comparators. We have shown that survivors Although a portion of these prescriptions were likely being used to treat or prevent acute post-therapy conditions (eg, infections), 2 observed patterns of prescription use suggest emerging chronic, treatment-related morbidities. First, the greater risk for many specific drug classes persists throughout all 3 years of the study period. Second, the risk associated with several classes of drugs appears to increase over time, including thyroid hormone among survivors of leukemia and lymphoma; pituitary and gonadal hormones among survivors of CNS tumors; bronchodilators among survivors of gonadal tumors; and ACE inhibitors among survivors of lymphoma. These observations, coupled with previous reports of increased use of pain medications 9 and antihypertensives 12 among long-term survivors, suggest that we are observing the emergence of chronic medical morbidities in the early post-therapy period. This is further suggested by our previous observation that the survivors of leukemia and lymphoma experienced increased rates of hospitalizations during this same time period as compared with matched controls.
18
Our findings support those of previous studies demonstrating increased prescription use among survivors. Although these earlier studies generally have focused on psychoactive medications and long-term survivors, 9-11 our current work examined multiple drug classes and patients who have been treated with current regimens. Similar to previous reports, 10, 11 we observed increased risks for use of antidepressants and anxiolytics for survivors of all cancer types. A prior study using the Childhood Cancer Survivor Study data comparing survivors with siblings did not observe an increased risk for antidepressant use among survivors; however, increased risks for anxiolytic, anticonvulsant, and opioid pain medications were noted. 9 In our analysis, antidepressant use among comparators was consistent with the known age-appropriate prevalence of depression (3%-4% in prepubertal and 6% in the postpubertal).
19
The percent of survivors filling an antidepressant prescription was 2-4 times that of children without cancer. This increased risk persisted for antidepressant prescriptions among survivors of most cancer types into the third year posttherapy-a similar pattern to anxiolytic medication fills.
These findings underscore the importance for mental health screening among survivors even during the early post-therapy period. Nearly 10% of CNS and bone tumor survivors (patients often treated with highly complex and intense multimodal regimens) continued to fill prescriptions for anxiolytics into the third year post-therapy, >4 times the risk of comparators. It is possible that survivors experience greater rates of anxiety and depression as sequelae of more intensive therapy. Indeed, we observed an overall trend for increased risk of medication use among survivors of CNS and bone cancers compared with survivors of gonadal cancers. This may be the result of more intensive therapy among those treated for brain and bone cancers (often multimodal, including surgery, chemotherapy, and radiation) vs those treated for gonadal cancers (frequently treated with surgery alone). However, as the exact indication for prescription use is not ascertainable with this data source, the increased use of these drugs also could reflect other morbidities in these populations (eg, seizures in the survivors of CNS tumors or neuropathic pain in the survivors of bone cancer).
With increasing concern regarding opioid prescribing trends, we were particularly interested in understanding the patterns of opioid use with time from EOT. Consistent with reports from the Childhood Cancer Survivor Study, 9 survivors of cancer in our analysis had an increased risk for receiving opioids in each year observed. In the third post-therapy year, nearly 30% of survivors of bone cancer, 20% of survivors of lymphoma and gonadal cancer, and 10% of survivors of leukemia and CNS tumors received an opioid medication in contrast to 7%-13% of comparators. Our observed percentage of comparators with an opioid fill is greater than a previous report for children without cancer from the same time period that used data from the Medical Expenditure Panel Surveys. That study reported that annually 3% of a population-based sample of children and adolescents without cancer had filled an opioid prescription, 20 a lower rate that may be due to underestimation from survey data.
Nevertheless, these findings indicate that chronic pain remains a significant morbidity among survivors even 3 years off therapy. Interestingly, a previous survey-based study of adolescent survivors of childhood cancers reported that survivors were less likely than peers to use alcohol, tobacco, and illicit drugs except for the nonmedical use of pain relievers. Survivors within 5 years of diagnosis were the most likely to participate in such use. 21 In light of these findings, with time from completion of therapy, it may be important for providers to consider methods other than opioids for treatment of chronic pain in this population.
Our findings must be interpreted in the context of certain limitations. The indication for medication use is not assessable through insurance claims data, yet an understanding of likely indication for use can be inferred by examining cancerspecific (and thus therapy-specific) patterns of use. This is particularly an issue during the first year post-therapy, when prescriptions for medications such as anti-infectives, pain medications, and anxiolytics may reflect ongoing prophylaxis or use in planned off-therapy procedures (line removal). However, the use of drugs from many classes (antihypertensives, thyroid hormone, and antidepressants) is increased among survivors in the first year off therapy and the increased use of antiinfectives, pain medications, and anxiolytics persist into the third year post-therapy. In addition, providers may be biased in prescribing more medications to survivors of cancer (antibiotics, pain medications), or survivors of cancer are prescribed more medications simply as the result of their greater engagement with the healthcare system. Although we are unable to clarify this, and likely no study would be able, the fact remains that survivors fill more prescriptions than their peers and the increased burden of healthcare use is clear.
Our data source could be limited in identifying the EOT for certain subsets of patients. For instance, a patient who transitioned to palliative therapy from active therapy may have been misclassified as a survivor. Among these patients, opioids may have been used for palliation of ongoing cancer symptoms as opposed to the treatment of therapy-related comorbidities. Although this is possible, it would be a rare and unlikely event, as few childhood and adolescent patients with cancer would survive for 3 years with palliative care alone and no further salvage therapy. Restricting our analysis to survivors with 3 years of continuous enrollment following the EOT limits the size of the study sample; however, that restriction allows us to say with confidence that survivors identified for this study did not have subsequent claims for chemotherapy, radiation therapy, or surgery that would be associated with active treatment. Although death is not recorded in claims, our requirement that individuals be continuously enrolled during the 3 years following EOT should exclude those who died during the follow-up period. Last, our study sample is restricted to privately insured children, and prescription drug use among children without insurance or with other sources of insurance may differ. However, previous work has shown increased odds for prescription fills among survivors whose family income is less than $20 000, 9 suggesting that survivors with publicly funded insurance are more likely to fill prescriptions than those with private insurance. Therefore, our estimates may be conservative.
Overall, our findings demonstrate increased prescription drug use among child and adolescent survivors of cancer and suggest the emergence of chronic medical morbidities in the early posttherapy period. As cancer treatment regimens evolve and the number of survivors continues to increase, up-to-date assessments of treatment-associated morbidities will be necessary to provide optimal risk-based survivorship care. General pediatricians and subspecialists alike must be aware of the significant psychiatric and medical morbidities faced by cancer survivors even during the early-post therapy period, a period of significant transition with potential for missed opportunities in care. ■ Submitted for publication Jun 6, 2017 
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The Effect of Pretreatment with Pentobarbital, Meperidine, or Hyperbaric Oxygen on the Response to Anoxia and Resuscitation in Newborn Rabbits
Campbell AGM, Milligan JE, Talner NS. J Pediatr 1968;72:518-27 F ifty years ago, as today, there was an intense search for neuroprotective therapeutic principles following birth asphyxia. One of the leading groups in the field was located at the Nuffield Institute of Medical Research in Oxford, where famous animal experiments were carried out. Here Campbell et al induced anoxia in a newborn rabbit model in a chamber flushed with nitrogen. Some minutes after the last gasp, resuscitation was carried out with hyperbaric oxygen. Animals were divided into different groups according to pretreatment with sodium pentobarbital or meperidine (pethidine or Demerol). Although these 2 drugs had some influence on time to last gasp and recovery compared with a control group not pretreated before anoxia was induced, no significant difference in survival in animals administered these drugs was found. However, a third group of animals treated with hyperbaric oxygen for 30 minutes before anoxia had a significantly lower survival despite no change in their pattern to anoxia when compared with controls, 26% vs 65% (P < .01).
A major discovery was made in this study: pretreatment with hyperbaric oxygen increases mortality after anoxia/ resuscitation. The authors speculated "that hyperbaric oxygen may cause a massive discharge of the sympathetic nervous system," which results in pulmonary damage leading to decreased survival. At that time, the effect of oxygen free radicals and oxidative stress on newborn health and disease was not known. It took almost 20 years until this was understood. 1 Today, these fundamental findings could be explained through such mechanisms. However, the finding that pretreatment with hyperbaric oxygen before an episode of anoxia is detrimental is still relevant, indicating the potential hazards of preoxygenating newborn children before procedures such as intubation. Today, we know even a brief exposure to hyperoxia right after birth may induce long-term detrimental effects. 
